Seven-Day Vein-to-Vein Point-of-Care–Manufactured CD19 CAR T-Cell Therapy (GLPG5201) in R/R CLL Including Richter Transformation: Results from the Phase 1 Euplagia-1 Trial

​Natalia Tovar

​16/02/2024